[1]Patent:WO2006/14357,2006,A1.Locationinpatent:Page/Pagecolumn80
[2]Patent:WO2006/14357,2006,A1.Locationinpatent:Page/Pagecolumn80-81
[1]CurrentPatentAssignee:CONCERTPHARMACEUTICALSINC-US2008/242711,2008,A1Locationinpatent:Page/Pagecolumn15-16
[1]CurrentPatentAssignee:MERCK&COINC-WO2010/39474,2010,A1Locationinpatent:Page/Pagecolumn11
[1]CurrentPatentAssignee:MERCK&COINC-WO2010/39474,2010,A1Locationinpatent:Page/Pagecolumn43
875446-37-0
[1]CurrentPatentAssignee:MERCK&COINC-WO2007/5572,2007,A1Locationinpatent:Page/Pagecolumn11-12
Title: Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
Journal: The Journal of clinical investigation 20150601
Title: Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Journal: Lancet (London, England) 20150530
Title: Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Journal: The Journal of pharmacology and experimental therapeutics 20150401
Title: Future of cholesteryl ester transfer protein inhibitors.
Journal: Annual review of medicine 20140101
Title: Tangier disease: epidemiology, pathophysiology, and management.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001
Title: Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
Journal: Journal of lipid research 20120901
Title: Rationale for cholesteryl ester transfer protein inhibition.
Journal: Current opinion in lipidology 20120801
Title: HDL and CETP Inhibition: Will This DEFINE the Future?
Journal: Current treatment options in cardiovascular medicine 20120801
Title: Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
Journal: Expert review of cardiovascular therapy 20120801
Title: Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Journal: British journal of clinical pharmacology 20120701
Title: Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Journal: European heart journal 20120701
Title: An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Journal: Future cardiology 20120701
Title: Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Journal: Current clinical pharmacology 20120501
Title: Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20120501
Title: On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Journal: Drugs 20120305
Title: Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.
Journal: Journal of lipid research 20120301
Title: New horizons for cholesterol ester transfer protein inhibitors.
Journal: Current atherosclerosis reports 20120201
Title: Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
Journal: Clinical pharmacology and therapeutics 20120101
Title: SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20120101
Title: Anacetrapib, a cholesteryl ester transfer protein inhibitor.
Journal: Expert opinion on investigational drugs 20120101
Title: Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.
Journal: PLoS computational biology 20120101
Title: Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.
Journal: Nutrition & metabolism 20120101
Title: Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Journal: Vascular health and risk management 20120101
Title: Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Journal: Core evidence 20120101
Title: Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Journal: Vascular health and risk management 20120101
Title: Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Journal: Drug design, development and therapy 20120101
Title: [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Journal: MMW Fortschritte der Medizin 20111208
Title: Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Journal: Cardiovascular therapeutics 20111201
Title: Familial hypercholesterolemia: present and future management.
Journal: Current cardiology reports 20111201
Title: Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.
Journal: Journal of lipid research 20111201
Title: Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
Journal: Biopharmaceutics & drug disposition 20111201
Title: Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Journal: Trends in pharmacological sciences 20111201
Title: Update on therapies targeting HDL: the mystery continues.
Journal: Current opinion in lipidology 20111201
Title: Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein.
Journal: Atherosclerosis 20111101
Title: Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Journal: Journal of lipid research 20111101
Title: Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Journal: Expert opinion on investigational drugs 20111101
Title: Anacetrapib: a new weapon against dyslipidemia.
Journal: Current clinical pharmacology 20111101
Title: Anacetrapib: hope for CETP inhibitors?
Journal: Cardiovascular therapeutics 20111001
Title: Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Journal: American heart journal 20111001
Title: Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Journal: Current opinion in lipidology 20110801
Title: Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
Journal: Journal of medicinal chemistry 20110714
Title: Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.
Journal: The AAPS journal 20110601
Title: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Journal: European heart journal 20110601
Title: The cholesterol ester transfer protein inhibitor, anacetrapib.
Journal: Current opinion in lipidology 20110601
Title: [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope'].
Journal: Revista medica de Chile 20110601
Title: A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.
Journal: Diabetes 20110401
Title: Preparative scale synthesis of the biaryl core of anacetrapib via a ruthenium-catalyzed direct arylation reaction: unexpected effect of solvent impurity on the arylation reaction.
Journal: The Journal of organic chemistry 20110304
Title: Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
Journal: Journal of clinical pharmacology 20110301
Title: The DEFINE study: a bright future for CETP inhibitors?
Journal: Expert opinion on investigational drugs 20110301
Title: Clinical Trials Update AHA Congress 2010.
Journal: Cardiovascular drugs and therapy 20110201
Title: CETP inhibition shows promise as way to reduce cardiovascular disease risk.
Journal: JAMA 20110112
Title: Trial watch: hope renewed for strategy to raise HDL cholesterol.
Journal: Nature reviews. Drug discovery 20110101
Title: Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
Journal: The Annals of pharmacotherapy 20110101
Title: [Novel therapy for atherosclerosis and inflammatory vascular disease].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20110101
Title: Cardiovascular disease and dyslipidemia: beyond LDL.
Journal: Current pharmaceutical design 20110101
Title: Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds.
Journal: Journal of cheminformatics 20110101
Title: Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.
Journal: The open cardiovascular medicine journal 20110101
Title: Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
Journal: Drug design, development and therapy 20110101
Title: Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans.
Journal: PloS one 20110101
Title: Emerging therapeutic strategies to enhance HDL function.
Journal: Lipids in health and disease 20110101
Title: New insights into the mechanism of low high-density lipoprotein cholesterol in obesity.
Journal: Lipids in health and disease 20110101
Title: Medical angioplasty - hope and expectations: an optimistic overview.
Journal: Journal of family & community medicine 20110101
Title: Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Journal: The New England journal of medicine 20101216
Title: Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Journal: Journal of lipid research 20101201
Title: Good news for 'good' cholesterol.
Journal: Nature 20101118
Title: Emerging drugs for hyperlipidemia.
Journal: Expert opinion on emerging drugs 20100901
Title: Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Journal: Journal of lipid research 20100901
Title: Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
Journal: PLoS computational biology 20100901
Title: Dissociating HDL cholesterol from cardiovascular risk.
Journal: Lancet (London, England) 20100731
Title: Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20100701
Title: Dalcetrapib: a review of Phase II data.
Journal: Expert opinion on investigational drugs 20100601
Title: [Recent advances in the research on HDL subfraction].
Journal: Rinsho byori. The Japanese journal of clinical pathology 20100601
Title: High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.
Journal: Current pharmaceutical design 20100501
Title: Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100301
Title: Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100301
Title: [HDL and CETP in atherogenesis].
Journal: Deutsche medizinische Wochenschrift (1946) 20100201
Title: Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Journal: European heart journal 20100101
Title: Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
Journal: Vascular health and risk management 20100101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20100101
Title: Anacetrapib.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101
Title: Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.
Journal: Lipids in health and disease 20100101
Title: Update on CETP inhibition.
Journal: Journal of clinical lipidology 20100101
Title: Treatment of dyslipidemia in patients with type 2 diabetes.
Journal: Lipids in health and disease 20100101
Title: High density lipoproteins-based therapies for cardiovascular disease.
Journal: Journal of cardiovascular disease research 20100101
Title: The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Journal: The American journal of cardiology 20091116
Title: Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Journal: Diabetes care 20091101
Title: Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Journal: American heart journal 20091001
Title: Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Journal: British journal of clinical pharmacology 20091001
Title: Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Journal: Expert opinion on therapeutic patents 20090901
Title: Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Journal: Current opinion in investigational drugs (London, England : 2000) 20090901
Title: The end of the road for CETP inhibitors after torcetrapib?
Journal: Current opinion in cardiology 20090701
Title: Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
Journal: American heart journal 20090701
Title: Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.
Journal: PLoS computational biology 20090501
Title: Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Journal: British journal of clinical pharmacology 20090501
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090401
Title: Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Journal: American heart journal 20090201
Title: Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Journal: Journal of clinical pharmacology 20090101
Title: High-density lipoprotein cholesterol: current perspective for clinicians.
Journal: Angiology 20090101
Title: Raising HDL cholesterol in women.
Journal: International journal of women's health 20090101
Title: Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Journal: Clinical pharmacology and therapeutics 20081201
Title: JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Journal: Expert opinion on investigational drugs 20081001
Title: The failure of torcetrapib: what have we learned?
Journal: British journal of pharmacology 20080801
Title: Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Journal: British journal of pharmacology 20080801
Title: Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia.
Journal: Nature clinical practice. Cardiovascular medicine 20080601
Title: Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Journal: Current atherosclerosis reports 20080601
Title: Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
Journal: Expert opinion on investigational drugs 20080401
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20080301
Title: HDL metabolism and CETP inhibition.
Journal: Cardiology in review 20080101
Title: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Journal: Lancet (London, England) 20071208
Title: Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51(12), 3443-3454.
Title: Dong B, et al. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014 Aug;235(2):449-62.
Title: Tan EY, et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos. 2010, 38(3), 459-473.
